{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-22-000094","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.596403+00:00","generated_at":"2026-06-21T07:25:57.402843+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"iBio prices $3.5M underwritten public offering of common stock and warrants","bullets":["Offering includes 3,365,385 shares (or pre-funded warrants) and Series A/B warrants with $1.04 exercise price.","Net proceeds to the company are approximately $2.9 million, used for operating costs, R&D, working capital, and debt payments.","Closing expected on or about December 9, 2022, subject to customary conditions. H.C. Wainwright is sole book-runner.","Underwriter granted 30-day option to purchase up to an additional 504,807 shares and/or warrants.","Representative’s Warrants issued to purchase 6% of offering shares at $1.30 exercise price, 5-year term."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-22-000094","json":"https://secwatch.observer/filing/0001420720-22-000094.json","markdown":"https://secwatch.observer/filing/0001420720-22-000094.md","text":"https://secwatch.observer/filing/0001420720-22-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000094/0001420720-22-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000094/ibio-20221206x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:25:57.402843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89e395861f5ca457a2ee07a05d0c588ecb61188b","claim":"iBio, Inc. entered into Underwriting Agreement with H.C. Wainwright & Co., LLC valued at approximately $2.9 million (effective 2022-12-06).","evidence_excerpt":"On December 6, 2022, iBio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072022000094/0001420720-22-000094-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Value","value":"approximately $2.9 million"},{"label":"Effective","value":"2022-12-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}